announced today that newly published data from a multicenter, prospective trial show that sacral nerve stimulation using Medtronic InterStim® Therapy reduced incontinent episodes and increased quality ...
DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...
Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...
A new multicenter study shows use of Medtronic’s InterStim Therapy via sacral nerve stimulation reduced incontinent episodes and improved quality of life in most patients with chronic fecal ...
The race to treat a number of health conditions using neurostimulation technology is a marathon, not a sprint—but Medtronic and Axonics Modulation Technologies are still aiming for a photo finish. For ...
Medtronic plc today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation of the InterStim™ portfolio’s recharge-free device – and it ...
SIOUX CITY | Amanda Sweum was convinced she would have to wear diapers for the rest of her life, until the 41-year-old Sioux City woman had a small device implanted in her lower back that put an end ...
(BPT) - It was the everyday struggles that really got to Peggy Smith. Smith couldn’t even make it to the grocery store without stopping to find a bathroom, let alone enjoy activities with her family ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback